I read with great interest the paper by Ellis et al. [
[1]
], which is a retrospective cohort study to determine the incidence of bleeding in
patients with atrial fibrillation (AF) beginning dabigatran, rivaroxaban or warfarin
during 3-year. Bleeding incidences were calculated per 100 patient-years of treatment,
and they were 3.9 (95% confidence interval (CI), 3.6–4.4) in warfarin patients, 4.2
(95% CI, 3.7–4.7) in dabigatran patients, and 4.1 (95% CI, 3.0–5.3) in rivaroxaban
patients. In addition, intracranial hemorrhage (ICH) rates were 0.71 (95% CI, 0.56–0.90)
in warfarin patients, 0.4 (95% CI, 0.18–0.87) in dabigatran patients, and 0.27 (95%CI,
0.10–0.80) in rivaroxaban patients. The authors recognized no significant differences
in the prevalence of bleeding and ICH in dabigatran and rivaroxaban patients against
warfarin patients. I have some queries on their study.Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: a retrospective population-based cohort study.Eur J Intern Med. 2016; 33: 55-59
- Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real-world” observational study in the United States.Int J Clin Pract. 2016; 70: 752-763
- XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.Eur Heart J. 2016; 37: 1145-1153
- Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27,467 patients taking rivaroxaban.Clin Cardiol. 2015; 38: 63-68
- Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.Curr Med Res Opin. 2016; 32: 2047-2053
Article info
Publication history
Published online: December 02, 2016
Accepted:
November 29,
2016
Received:
November 27,
2016
Identification
Copyright
© 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
